Your browser is no longer supported. Please, upgrade your browser.
Settings
CLDX Celldex Therapeutics, Inc. daily Stock Chart
CLDX [NASD]
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.30 Insider Own0.30% Shs Outstand123.32M Perf Week-7.39%
Market Cap402.02M Forward P/E- EPS next Y-1.15 Insider Trans0.82% Shs Float121.45M Perf Month-2.40%
Income-128.90M PEG- EPS next Q-0.33 Inst Own68.60% Short Float16.19% Perf Quarter-28.04%
Sales6.70M P/S60.00 EPS this Y0.80% Inst Trans17.63% Short Ratio10.92 Perf Half Y-6.86%
Book/sh2.16 P/B1.51 EPS next Y12.20% ROA-44.30% Target Price8.00 Perf Year-52.82%
Cash/sh1.65 P/C1.98 EPS next 5Y- ROE-51.50% 52W Range2.85 - 8.75 Perf YTD-7.91%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.74% Beta2.84
Dividend %- Quick Ratio11.30 Sales past 5Y-34.90% Gross Margin- 52W Low14.39% ATR0.15
Employees196 Current Ratio11.30 Sales Q/Q120.00% Oper. Margin- RSI (14)39.99 Volatility4.01% 4.55%
OptionableYes Debt/Eq0.00 EPS Q/Q9.40% Profit Margin- Rel Volume0.65 Prev Close3.26
ShortableYes LT Debt/Eq0.00 EarningsMar 02 AMC Payout- Avg Volume1.80M Price3.26
Recom2.30 SMA20-3.68% SMA50-8.11% SMA200-17.17% Volume1,170,450 Change0.00%
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jan-10-13Reiterated Cantor Fitzgerald Buy $9 → $13
Oct-02-12Reiterated Oppenheimer Outperform $6 → $8
Sep-14-12Reiterated Cantor Fitzgerald Buy $7 → $9
Apr-04-12Initiated Cantor Fitzgerald Buy $7
Nov-02-11Reiterated Brean Murray Buy $16 → $14
Feb-24-17 05:42PM  3 Biotech Long Shots: Boom Or Bust? at Motley Fool
Feb-23-17 07:44PM  Looking Back at David Gardner's Worst Stock Picks of the Past 3 Years at Motley Fool
Feb-13-17 02:45PM  Celldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call GlobeNewswire
Feb-09-17 09:48AM  Why Celldex Therapeutics Stock Fell by Almost 10% in January at Motley Fool
Feb-07-17 04:04PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statem
Feb-06-17 07:45AM  3 Stocks That Could Make You Rich at Motley Fool
Feb-03-17 09:30AM  Mergers & Acquisitions Could be a Key Catalyst for Biotech Stocks in 2017: Today's Reports on Cellect Biotechnology and Celldex Therapeutics Accesswire
Feb-01-17 08:14AM  Forget Celldex Therapeutics, Inc.: These 2 Stocks Are Better Buys at Motley Fool
Jan-30-17 03:12PM  3 Biotech Stocks I'd Buy Right Now at Motley Fool
Jan-26-17 04:28PM  5 Small-Cap Biotech Stocks to Buy in February at Motley Fool
Jan-20-17 10:41AM  3 Beaten-Down Biotech Stocks You Can Buy Right Now at Motley Fool
Jan-10-17 10:36AM  Celldex Therapeutics, Inc. Value Analysis (NASDAQ:CLDX) : January 10, 2017
09:09AM  Why Celldex Therapeutics Imploded in 2016 at Motley Fool
Jan-09-17 07:19AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : January 9, 2017
Jan-06-17 01:26PM  Celldex Therapeutics, Inc.'s 3 Best Moves in 2016 at Motley Fool
Dec-24-16 02:52PM  Better Buy: Celldex Therapeutics, Inc. vs. Exelixis at Motley Fool
Dec-22-16 09:36AM  2016's Worst Clinical Failures at Motley Fool
09:24AM  2016 Was a Terrible Year for Biotech but the Tweets Were on Point
Dec-20-16 09:15AM  Latest Reports on Biotech Movers MannKind and Celldex Therapeutics Accesswire
Dec-19-16 02:51PM  How to Value Clinical-Stage Biotech Stocks at Motley Fool
07:18AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : December 19, 2016
Dec-15-16 02:51PM  Celldex Therapeutics, Inc.'s Biggest Failure in 2016 at Motley Fool
Dec-14-16 04:09PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F
04:01PM  Celldex Therapeutics Announces Appointment to Board of Directors GlobeNewswire
Dec-13-16 12:22PM  3 Cheap Healthcare Stocks You Can Buy Right Now at Motley Fool
Dec-11-16 12:06PM  Celldex Therapeutics, Inc.'s Biggest Win in 2016 at Motley Fool
Dec-10-16 07:32PM  Is Celldex Therapeutics, Inc. (CLDX) a Good Stock To Buy? at Insider Monkey
Dec-08-16 12:23PM  ETFs with exposure to Celldex Therapeutics, Inc. : December 8, 2016
Dec-07-16 11:12AM  Is Celldex Therapeutics (CLDX) Stock a Solid Choice Right Now?
10:01AM  Why Celldex Rallied 22% In November at Motley Fool
Dec-06-16 05:53PM  Why You Should (and Shouldn't) Buy Celldex Therapeutics, Inc. at Motley Fool
Dec-05-16 04:04PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F +6.76%
04:01PM  Theresa LaVallee, Ph.D., Joins Celldex Therapeutics Senior Management Team GlobeNewswire
08:01AM  Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Dec-02-16 01:17PM  The Worst Biotech Stocks of 2016 at Motley Fool
Dec-01-16 07:32AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : December 1, 2016 -6.30%
Nov-29-16 04:05PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistered Sale
04:01PM  Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals GlobeNewswire
08:17AM  Down 11.7%: Is Celldex Therapeutics Now a Buy? at Motley Fool
Nov-23-16 12:47PM  ETFs with exposure to Celldex Therapeutics, Inc. : November 23, 2016
Nov-22-16 10:27AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
Nov-21-16 07:03AM  Ready to Get In on Biotech? Check Out These 3 Stocks at Motley Fool +5.64%
Nov-17-16 01:04PM  CELLDEX THERAPEUTICS, INC. Financials
Nov-15-16 02:24PM  Celldex Cancer Drug Did Well in Early Trial (CLDX) at Investopedia
08:03AM  Celldex Stock Up on Positive Data on New Cancer Candidate
Nov-14-16 03:58PM  Why Celldex Therapeutics, Inc. Stock Jumped Higher Again Today at Motley Fool +13.89%
08:01AM  Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody GlobeNewswire
Nov-09-16 04:41PM  Why Celldex Therapeutics, Inc. Stock Tumbled 22% in October at Motley Fool +6.61%
03:45PM  Celldex (CLDX) Q3 Loss Narrower than Expected, Sales Beat
07:26AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2016
Nov-08-16 12:51PM  Why Celldex Therapeutics, Inc. Jumped Higher Today at Motley Fool +14.89%
10:50AM  Celldex 3Q Loss $30M, or 29 Cents a Share (CLDX) at Investopedia
Nov-07-16 06:21PM  Celldex Therapeutics, Inc. Watches Its Cash in Q3, Ready to Expand at Motley Fool +6.47%
05:31PM  Celldex reports 3Q loss
04:07PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:01PM  Celldex Reports Third Quarter 2016 Results GlobeNewswire
09:37AM  Coverage initiated on Celldex Therapeutics by Aegis Capital
Nov-03-16 08:49AM  Biotech Stock Roundup: Amgen Down on Enbrel Sales, Regeneron's Sarilumab Faces Delay -8.89%
08:15AM  Blog Coverage Celldex Acquires Cancer Medicine Company for $62.5 Million Accesswire
Nov-02-16 01:55PM  Celldex Buys Cancer Drug Co. for $62M Stock (CLDX) at Investopedia
11:33AM  3 Biotech Stocks That Could Double in 12 Months at Motley Fool
09:50AM  9 Biotech Stocks to Put on Your Radar at Kiplinger
Nov-01-16 04:08PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
04:02PM  Celldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals GlobeNewswire
Oct-31-16 08:50AM  Celldex (CLDX): Will the Stock Surprise in Q3 Earnings?
Oct-26-16 11:15AM  Better Buy: Celldex Therapeutics, Inc. vs. bluebird bio, Inc. at Motley Fool
Oct-19-16 11:26AM  ETFs with exposure to Celldex Therapeutics, Inc. : October 19, 2016
07:05AM  Better Buy: NantKwest, Inc. vs. Celldex Therapeutics, Inc. at Motley Fool
Oct-18-16 09:23AM  Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status CNW Group
Oct-17-16 08:02AM  Is This Risky Biotech Stock About to Jump Higher? at Motley Fool
Oct-12-16 08:43AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : October 12, 2016
Oct-11-16 04:30PM  These 3 Little Biotechs Just Scored Big at Motley Fool -8.96%
09:15AM  Blog Coverage Celldex Phase II Study of Glembatumumabvedotin Show Positive Results Accesswire
09:05AM  Blog Coverage Celldex Phase II Study of Glembatumumabvedotin Show Positive Results
Oct-09-16 07:00AM  Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint and Demonstrates Clinically Meaningful Duration of Response GlobeNewswire
Oct-05-16 02:42PM  Three Cancer Plays For The Fourth Quarter Of 2016 at Insider Monkey
02:35PM  4 breakout stocks to watch at MarketWatch
Oct-04-16 05:46PM  Why Endurance Specialty Holdings, Celldex Therapeutics, and Sears Holdings Jumped Today at Motley Fool +6.75%
01:29PM  Why Celldex Therapeutics, Inc. Jumped Higher Today at Motley Fool
09:15AM  Key FDA Decisions and Trial Results Expected in October at 24/7 Wall St.
08:56AM  Forget Celldex Therapeutics, Inc.: These 2 Stocks Doubled Last Year at Motley Fool
08:27AM  3 Beaten-Up Healthcare Stocks: Are They Bargains? at Motley Fool
Sep-30-16 09:44AM  ETFs with exposure to Celldex Therapeutics, Inc. : September 30, 2016 +6.32%
Sep-29-16 10:07AM  Celldex Therapeutics, Inc. Value Analysis (NASDAQ:CLDX) : September 29, 2016
Sep-28-16 08:07AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : September 28, 2016 -5.67%
Sep-27-16 04:26PM  Why Celldex Therapeutics, Inc. Ran Higher Today at Motley Fool +11.32%
09:54AM  3 Stocks That Could Make You Rich at Motley Fool
Sep-23-16 11:30AM  Celldex Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable GlobeNewswire
Sep-20-16 08:36PM  Celldex Therapeutics Remains a Guessing Game at Investopedia
Sep-14-16 08:20AM  Key FDA Decisions and Trial Results Coming in the Next 2 Months at 24/7 Wall St.
Sep-12-16 10:41AM  ETFs with exposure to Celldex Therapeutics, Inc. : September 12, 2016 +7.54%
08:09AM  Why Celldex Therapeutics, Inc. Stock Sank 28.1% in August at Motley Fool
Sep-08-16 08:05AM  Key FDA Decisions and Trial Results Expected in October at 24/7 Wall St.
Aug-29-16 11:13AM  ETFs with exposure to Celldex Therapeutics, Inc. : August 29, 2016
Aug-26-16 04:41PM  3 Reasons Celldex Therapeutics, Inc. Stock Could Fall at Motley Fool
Aug-18-16 06:15PM  ETFs with exposure to Celldex Therapeutics, Inc. : August 18, 2016
Aug-17-16 09:29AM  Biotech Industry on the Upswing after Rocky Start to 2016
Aug-16-16 09:55AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 16, 2016
Aug-12-16 01:42PM  How Risky Is Celldex Therapeutics, Inc.? at Motley Fool
Aug-11-16 08:04AM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care. The company's lead drug candidates comprise Rintega (CDX-110), a therapeutic vaccine in Phase III clinical studies for the treatment of glioblastoma patients that express an epidermal growth factor receptor variant III, as well as in Phase II study for the treatment of recurrent glioblastoma; Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate (ADC) in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma; and Varlilumab (CDX-1127), an immune modulating antibody is in Phase I study for the treatment of multiple solid tumors. It also has various earlier stage drug candidates in clinical development, including CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, a fully-human monoclonal ADC that targets T cell immunoglobulin and mucin domain 1, a molecule, which is upregulated in various cancers comprising renal cell and ovarian carcinomas. In addition, the company is developing CDX-0158, which is in a Phase I dose escalation study in refractory gastrointestinal stromal tumors; CDX-3379 that completed a Phase Ib study for adult patients with advanced solid tumors; and a multi-faceted TAM program to generate antibodies that modulate the TAM family of RTKs comprising of Tyro3, AXL, and MerTK. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc., as well as clinical trial collaboration with Roche Holding. The company is headquartered in Hampton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CATLIN AVERY WSr. VP & CFOSep 02Option Exercise2.8010,00028,00083,586Sep 07 12:59 PM
KELER TIBORExecutive VP & CSOSep 02Buy3.323,0009,96018,868Sep 06 01:04 PM
CATLIN AVERY WSr. VP & CFOJun 03Option Exercise3.0122,84768,81273,586Jun 06 08:26 AM
CATLIN AVERY WSr. VP & CFOMar 09Option Exercise2.8015,00042,00050,739Mar 10 07:59 AM